Advances in Biopreservation - J.G. Baust, Bio Med 1
[ Pobierz całość w formacie PDF ]
Advances in
BIOPRESERVATION
Edited by
JOHN G. BAUST
Institute of Biomedical Technology
State University of New York
Binghamton, New York
JOHN M. BAUST
Cell Preservation Services, Inc.
Owego, New York
Boca Raton London New York
CRC is an imprint of the Taylor & Francis Group,
an informa business
© 2007 by Taylor & Francis Group, LLC
CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487‑2742
© 2007 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business
No claim to original U.S. Government works
Printed in the United States of America on acid‑free paper
10 9 8 7 6 5 4 3 2 1
International Standard Book Number‑10: 0‑8493‑2772‑5 (Hardcover)
International Standard Book Number‑13: 978‑0‑8493‑2772‑8 (Hardcover)
This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted
with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to
publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of
all materials or for the consequences of their use.
No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or
other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any informa‑
tion storage or retrieval system, without written permission from the publishers.
For permission to photocopy or use material electronically from this work, please access
(http://
www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923,
978‑750‑8400. CCC is a not‑for‑profit organization that provides licenses and registration for a variety of users. For orga‑
nizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.
Trademark Notice:
Product or corporate names may be trademarks or registered trademarks, and are used only for
identification and explanation without intent to infringe.
Library of Congress Cataloging‑in‑Publication Data
Advances in biopreservation / edited by John G. Baust and John M. Baust.
p. cm.
Includes bibliographical references and index.
ISBN 0‑8493‑2772‑5
1. Cryobiology. I. Baust, J. G. II. Baust, John M.
QH324.9.C7A46 2006
571.4’645‑‑dc22
2006004020
Visit the Taylor & Francis Web site at
and the CRC Press Web site at
© 2007 by Taylor & Francis Group, LLC
Preface
Sixty-five years have passed since the publication of Basil Luyet’s
Life and Death at Low Temper-
, the first organized attempt to summarize past observations of freezing injury in living
organisms and to infer from them the mechanisms of injury. Not surprisingly, attention at that time
was focused primarily on mechanical damage from ice, although, as evidence of the immaturity
of the science, Luyet considered five other possible mechanisms: the withdrawal of energy, attain-
ment of a minimal temperature, too-rapid thawing, dehydration, and “various physiological, phys-
ical, or chemical alterations.”
One might have expected that the subsequent years would have led to a clear and functional
understanding of freezing injury and, as a result, have enabled efficient cryopreservation of almost
anything. But it wasn’t that easy. Looking back at some of the hypotheses that emerged — salt
concentration (Lovelock), disulfide binding (Levitt), the two factor hypothesis (Mazur), minimum
volume (Meryman), membrane depletion (Williams, Steponkus) — one can see that, in retrospect,
each in a very general sense was correct, but none provided sufficient insight to lift applied
cryopreservation very far from the empirical. In fact, even after those sixty-plus years, our insight
is still pretty much limited to the recognition that intracellular ice is generally lethal, that ice nuclei
are rare or absent within cells, that extracellular ice concentrates the extracellular solution and the
cells lose water osmotically and shrink. However, the precise nature of the lethal event for each
cell type continues to be debatable, whether from the seeding of extracellular ice through membrane
pores, from membrane stresses leading to the loss of membrane material, from temperature- and
concentration-related denaturation or precipitation, or from some as-yet ill-defined phenomenon.
The role of cold denaturation of proteins has been largely ignored.
Fortunately — or, some might argue, unfortunately — the advent of penetrating cryoprotectants,
primarily glycerol and DMSO, has enabled empirical cryopreservation to leapfrog basic research.
Topics that were central to cryobiology research in the 1950s and 1960s have been overshadowed
by demonstrations of empirical success. Cryopreservation is increasingly being undertaken by
specialists in the subject tissue rather than by cryobiologists, and the practicalities of grant and
contract support tend to perpetuate this trend.
However, although the effectiveness of the penetrating cryoprotectants has made many basic
questions moot, the challenges are still far from resolved. The cryoprotectants themselves are now
the obstacles to easy success. Glycerol penetrates cells slowly and some cells not at all, creating
major osmotic problems. But glycerol has the great advantage of being a nontoxic macromolecular
stabilizer. DMSO, despite its reputation, does not cross membranes instantly; in fact, at temperatures
below 10°C, it enters cells relatively slowly — at least this is true for red cells. And it is a
macromolecular destabilizer with demonstrated toxicity.
From the purely practical aspect, it is better cryoprotectants that are needed. Polymers have
their own shortcomings and, with some exceptions, enable long-term, low-temperature storage only
in the presence of associated penetrating agents. Complete vitrification is a promising approach,
but there are still formidable obstacles to be surmounted. For an ideal penetrating agent, there are
only two criteria. Such an agent must cross cell membranes readily and rapidly and must be nontoxic
at elevated concentrations. Obvious candidates are low-molecular weight organic compounds or
cations such as ammonium compounds that are partially dissociated and enter the cell in the
uncharged form. However, there are a limited number of low-molecular weight compounds and
even the two simple criteria cited above may be too demanding.
ature
© 2007 by Taylor & Francis Group, LLC
This timely and impressive volume shows just how far cryobiology has come in providing
frozen preservation for a variety of cells and tissues and also how much dedicated effort it has
taken to get this far. It is also apparent that each individual cell type requires an individually crafted
cryoprotective regimen that may still achieve only limited recovery, and that the ultimate goals of
applied cryobiology have yet to be achieved. It is likely that the limitations of cryopreservation
apparent today will not be resolved just by more tinkering, but will require a return to the basic
questions that drove cryobiology during its earlier years. In the pharmaceutical industry, examples
abound of successful new therapeutics made possible only by an accurate understanding of the
process to be addressed. For cryopreservation, the easy answers are not good enough. The time is
ripe for more basic science.
Harold T. Meryman
© 2007 by Taylor & Francis Group, LLC
Editors
holds an appointment as a lead professor in the Departments of Biological
Sciences and Bioengineering, and is the Director of the Institute of Biomedical Technology at the
State University of New York at Binghamton. Dr. Baust directs multidisciplinary research programs
in cell/tissue cryopreservation, hypothermic organ preservation, tissue engineering, and cancer
therapy. He serves on several advisory and editorial boards of various biotech corporations and
journals including serving as Editor-in-Chief for
John G. Baust, Ph.D.,
Cell Preservation Technology
and board member
for the
. He has authored and co-authored hundreds of papers,
reviews, and abstracts and holds over 50 U.S. and international patents in the area of the low-
temperature sciences. Dr. Baust has founded, co-founded, or served on the advisory board of
numerous companies, including Mariseed, Inc., LifeCell,, Inc., Cryomedical Sciences, Inc., and
Cryocath Technologies, Ltd. He presently serves as President and CEO of BioLife Solutions, Inc.
International Society for Cryobiology
serves as the President and CEO of Cell Preservation Services, Inc.
(CPSI) and is a research assistant professor in the Departments of Bioengineering and Biology at
the State University of New York at Binghamton. Prior to founding CPSI, Dr. Baust served as
Director of Research for BioLife Solutions, Inc., following completion of a postdoctoral research
fellowship at the Center for Engineering in Medicine at Harvard Medical School and Massachusetts
General Hospital. Dr. Baust, who received his Ph.D. in cell and molecular biology from the State
University of New York, directs multidisciplinary research programs in cell/tissue cryopreservation,
hypothermic organ preservation, tissue engineering and cancer therapy. He serves on several
advisory and editorial boards of various biotech corporations and journals including the journal
John M. Baust, Ph.D.,
Cell Preservation Technology
. He also serves on the Board of Governors of the Society for
Cryobiology. He has authored and co-authored numerous papers, reviews, abstracts, and patents in
the area of the low-temperature biology and has been instrumental in the advancement of the field
of cryobiology into the molecular biological era, focusing in the areas of signal transduction and
apoptosis.
© 2007 by Taylor & Francis Group, LLC
[ Pobierz całość w formacie PDF ]